“Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials” (2025) SKIN The Journal of Cutaneous Medicine, 9(6), p. s660. doi:10.25251/1g590e41.